Conatus Pharmaceuticals Inc. (CNAT)
Symbol Info
Listed Symbol CNAT
Name Conatus Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $33,586,000
Latest Fiscal EPS $-0.59
Price Info
21 Day Moving Average $0.3383
21 Day EMA $0.331530
50 Day Moving Average $0.3281
50 Day EMA $0.361380
200 Day EMA $1.197920
200 Day Moving Average 1.034250
52 Week High $5.89
52 Week Low $0.25
52 Week Change $-93.125000
Alpha -0.019296
Beta 2.1370
Standard Deviation 0.337309
R2 0.047384
Periods 60
Share Information
10 Day Average Volume 527,507
20 Day Average Volume 531,477
30 Day Average Volume 905,102
50 Day Average Volume 735,077
Outstanding Shares 33,170,487
Float Shares 32,978,322
Percent Float 99.42%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 125
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 682,901
Institute Holdings Percent 21.700000
Institute Sold Previous 3 Months 1,029,289
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 0.60%
Insider Sold Previous 3 Months -
Insiders Shares Owned 192,165
Price Change
7 Day Price Change $0.0100000
7 Day Percent Change 3.13%
21 Day Price Change $-0.011
21 Day Percent Change -3.23%
30 Day Price Change $-0.0855
30 Day Percent Change -20.58%
Month To Date Price Change $0.0150
Month To Date Percent 4.76%
90 Day Price Change $-0.12
90 Day Percent Change -26.67%
Quarter To Date $0.015000
Quarter To Date Percent 4.76%
180 Day Price Change $-0.93
180 Day Percent Change -73.81%
200 Day Price Change $-0.87
200 Day Percent Change -72.50%
Year To Date $-1.4
Year To Date Percent -80.92%
Profile
Description Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.
Details
Issue Type CS
Market Cap $10,946,261
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 33,170,487
CEO Steven J. Mento
Employees 31
Last Audit UQ
Classification
CIK 0001383701
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 16745 West Bernardo Drive
Suite 200
San Diego, CA 92127
Website https://www.conatuspharma.com
Facisimile +1 858 558-8920
Telephone +1 858 376-2600
Email aengbring@conatuspharma.com
Key Ratios
Profitability
EBIT Margin -41.3
EBITDA Margin -41
Pre-Tax Profit Margin -
Profit Margin Cont -36.91
Gross Margin -
Profit Margin TOT -36.91
Income Statements
Revenue $25,224,000
Revenue Per Share $0.7604
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-17,765,297
Price To Sales 0.433962
Price To Free Cash -0.5
PE High Last 5 Years -
Price To Book 0.4
Price To Cash Flow 6.7
PE Low Last 5 Years -
Price To Tangible Book 0.4
Financial Strength
Total Debt To Equity 0.0
Int Coverage -41.9
Current Ratio 3.0
Leverage Ratio 1.2
Quick Ratio 2.7
Long Term Debt To Capital -
Assets
Receivables Turnover 2.4
Invoice Turnover -
Assets Turnover 0.20
Management Effectiveness
Return Assets -26.97
Return On Equity -63.06
Return On Capital -49.28
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
CNAT
Conatus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191015 18:30:30